Citations

Clear

367 citation(s) found for "Benson, Al".

Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
Nunnelee, Jordan , Cottini, Francesca , Zhao, Qiuhong , Faisal, Muhammad Salman , Elder, Patrick , Rosko, Ashley , Bumma, Naresh , Khan, Abdullah , Umyarova, Elvira , Devarakonda, Srinivas , Benson, Don M. , Efebera, Yvonne A. , Sharma, Nidhi

Mayo Clinic

Journal of Clinical Medicine | September 29, 2022 | Volume: 11 | Issue: 19 | Pages: 5794

10.3390/jcm11195794 | PMID 36233663 Get It

Maintenance therapy after autologous stem cell transplant (ASCT) in multiple myeloma (MM) is the standard treatment and recommended to be continued until disease progression. However, in the real world, patients discontinue treatment due to various reasons. We sought to determine the effect of early versus late discontinuation on survival outcomes in MM patients who underwent ASCT at The Ohio State University. We retrospectively reviewed 340 patients who underwent ASCT from 2005 to 2016 and received maintenance therapy for at least six months without progression. We compared the outcomes of patients who received maintenance for three years or less (early group) to the patients who continued maintenance beyond three years (late group). Lenalidomide (89%) and bortezomib (10%) were the most common agents used for maintenance chemotherapy. In Kaplan–Meier analysis, patients in the late group had prolonged progression-free (PFS) (p < 0.001) and overall survival (OS) (p < 0.001). The 5-year estimated OS in late group was 96% vs. 79% in the early group and 5-year PFS was 80% in late group vs. 50% in the early group. The most common reasons for discontinuation of maintenance in early group were adverse events (55.9%) and patient preference (22.5%). For the late group, it was disease progression (23.9%) and adverse events (14.3%). Fifty-five percent of patients in the late group were still on maintenance treatment at the last follow-up. Continuation of maintenance therapy was thus associated with improved outcomes, while adverse events prevented most patients from continuing treatment.
Photon-Counting Detector CT for Temporal Bone Imaging: Up to Three Times the Resolution at Half the Radiation Dose
Macielak, Robert J. , Lane, John I. , Carlson, Matthew L. , Benson, John C. , Leng, Shuai

Mayo Clinic

Otology & Neurotology | September 15, 2022 | Volume: 43 | Issue: 10 | Pages: e1205-e1207

10.1097/mao.0000000000003682 | PMID 36109120 Get It

MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls
Gaudioso, Cristina , Mar, Soe , Casper, T. Charles , Codden, Rachel , Nguyen, Adam, Aaen, Gregory , Chitnis, Tanuja , Francisco, Carla , Gorman, Mark , Greenberg, Benjamin , Hart, Janace, Lotze, Timothy , Narula, Sona , Pittock, Sean J. , Rose, John , Schreiner, Teri , Tillema, Jan‐Mendelt , Wheeler, Yolanda , Gaudioso, Cristina M , Chitnis, Tanuja , Graves, Jennifer , Pittock, S J , Waubant, Emmanuelle L. , Greenberg, Benjamin M , Nguyen, Adam, Benson, Leslie, Goyal, Manu S. , Graves, Jennifer , Krupp, Lauren , Rensel, Mary R. , Rodriguez, Moses , Schreiner, Teri , Waldman, Amy , Weinstock‐Guttman, Bianca , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | September 11, 2022 | Volume: 93 | Issue: 2 | Pages: 271-284

10.1002/ana.26502 | PMID 36088544 Get It

Objective The purpose of this study was to determine the frequency of myelin oligodendrocyte glycoprotein (MOG)‐IgG and aquaporin‐4 (AQP4)‐IgG among patients with pediatric‐onset multiple sclerosis (POMS) and healthy controls, to determine whether seropositive cases fulfilled their respective diagnostic criteria, to compare characteristics and outcomes in children with POMS versus MOG‐IgG‐associated disease (MOGAD), and identify clinical features associated with final diagnosis. Methods Patients with POMS and healthy controls were enrolled at 14 US sites through a prospective case–control study on POMS risk factors. Serum AQP4‐IgG and MOG‐IgG were assessed using live cell‐based assays. Results AQP4‐IgG was negative among all 1,196 participants, 493 with POMS and 703 healthy controls. MOG‐IgG was positive in 30 of 493 cases (6%) and zero controls. Twenty‐five of 30 patients positive with MOG‐IgG (83%) had MOGAD, whereas 5 of 30 (17%) maintained a diagnosis of multiple sclerosis (MS) on re‐review of records. MOGAD cases were more commonly in female patients (21/25 [84%] vs 301/468 [64%]; p = 0.044), younger age (mean = 8.2 ± 4.2 vs 14.7 ± 2.6 years; p < 0.001), more commonly had initial optic nerve symptoms (16/25 [64%] vs 129/391 [33%]; p = 0.002), or acute disseminated encephalomyelitis (ADEM; 8/25 [32%] vs 9/468 [2%]; p < 0.001), and less commonly had initial spinal cord symptoms (3/20 [15%] vs 194/381 [51%]; p = 0.002), serum Epstein–Barr virus (EBV) positivity (11/25 [44%] vs 445/468 [95%]; p < 0.001), or cerebrospinal fluid oligoclonal bands (5/25 [20%] vs 243/352 [69%]; p < 0.001). Interpretation MOG‐IgG and AQP4‐IgG were not identified among healthy controls confirming their high specificity for pediatric central nervous system (CNS) demyelinating disease. Five percent of those with prior POMS diagnoses ultimately had MOGAD; and none had AQP4‐IgG positivity. Clinical features associated with a final diagnosis of MOGAD in those with suspected MS included initial ADEM phenotype, younger age at disease onset, and lack of EBV exposure. ANN NEUROL 2023;93:271–284
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population
Udompap, Prowpanga , Therneau, Terry M. , Canning, Rachel, Benson, Joanne T., Allen, Alina M. , Allen, Alina M

Mayo Clinic

Hepatology | August 22, 2022 | Volume: 77 | Issue: 3 | Pages: 931-941

10.1002/hep.32739 | PMID 35989502 Get It

Background and aims: The American Gastroenterological Association (AGA) recently launched the Clinical Care Pathway for the Risk Stratification and Management of Patients with NAFLD to identify adults with significant fibrosis. We aimed to examine this pathway’s performance in the US population. Approach and Results: Using the 2017–2018 National Health and Nutrition Examination Survey data, we identified participants aged ≥18 with available Fibrosis‐4 (FIB‐4) score and liver stiffness measurement (LSM) in the absence of other liver diseases. Based on the AGA clinical pathway, FIB‐4 < 1.3 and LSM < 8 kilopascals (kPa) by vibration‐controlled transient elastography (VCTE) are associated with low risk of significant fibrosis. Using these cutoffs, we examined the pathway performance using negative predictive value (NPV) and positive predictive value (PPV) and explored alternative risk‐stratification strategies. There were 2322 participants with available data (projected to 94.2 million US adults). The NPV of LSM ≥ 8 kPa among those with FIB‐4 < 1.3 was 90%, whereas the PPV among those with FIB‐4 1.3–2.67 was 13%. As diabetes was a strong predictor of fibrosis, we propose a simple, alternative strategy to eliminate the indeterminate FIB‐4 range and perform VCTE in those with FIB‐4 ≥ 1.3 and diabetes. This strategy would decrease the number of VCTEs from 14.5 to 4.9 million and increase PPV from 13% to 33% without compromising the NPV among those who did not undergo VCTE. Conclusion: The implementation of the current AGA clinical pathway would lead to overutilization of VCTE. An alternative strategy using FIB‐4 ≥ 1.3 and diabetes to select adults undergoing second‐line testing will improve this pathway’s performance and minimize unnecessary VCTEs.
Co-Registration of pre- and post-Operative images after cochlear Implantation: A proposed technique to Improve cochlear visualization and localization of cochlear electrodes
Benson, John C. , Nassiri, Ashley M. , Saoji, Aniket A. , Carlson, Matthew L. , Lane, John I. , Benson, John

Mayo Clinic

The Neuroradiology Journal | August 19, 2022 | Volume: 36 | Issue: 2 | Pages: 194-197

10.1177/19714009221122180 | PMID 35985649 Get It

Background and Purpose After cochlear implantation, metallic artifact can obscure nearby structures on CT images, which is problematic in patients with facial nerve stimulation (FNS). This study evaluated the usefulness of co-registered pre- and post-operative examinations to evaluate the cochlear implant and adjacent structures. Materials and Methods A retrospective review was completed of consecutive patients that underwent CT imaging of the temporal bone before and after placement of a cochlear implant. Two blinded neuroradiologists independently reviewed all available examinations. All examinations were assessed for the presence or absence of dehiscence of the osseous ridge between the cochlea and facial nerve canal (FNC). Pre-operative and fused pre- and post-operative examinations were compared in their ability to visualize the osseous ridge using a 5-point Likert scale (ranging from 1 = unfused images were substantially superior to 5 = fused images were substantially superior). The electrode closest to the FNC were noted. Results Of 34 included patients, 13 (38.2%) were female and 21 (61.8%) were male; average age was 72.2. Seven patients (20.6%) had frank dehiscence between the cochlea and FNC. Fused images were superior to the post-operative study alone for assessing the integrity of the osseous partition between the cochlea and FNC and for reducing artifact from the electrode array (average Likert scores for both reviewers were 4.4 and 4.7). There was good agreement between reviewers in noting electrode closest to the FNC (concordance correlation coefficient=0.82). Conclusions Following cochlear implantation, co-registered pre- and post-operative CT images are superior to conventional images in assessing the anatomic relationship between the cochlea and FNC.
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial
Sinicrope, Frank A. , Shi, Qian , Catteau, Aurélie , Poage, Graham M. , Mlecnik, Bernhard , Benson, Al B. , Gill, Sharlene , Goldberg, Richard M. , Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Smyrk, Thomas C. , Mlecnik, Bernhard , Benson, Al , Gill, Sharlene , Goldberg, Richard M , Nair, Suresh , Shields, Anthony F , Galon, Jerome , Alberts, Steven R , Sinicrope, Frank A , Shi, Qian , Zemla, Tyler , Galon, Jérôme , Alberts, Steven R.

Mayo Clinic

JCO Precision Oncology | August 11, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.22.00010 | PMID 35952316 Get It

PURPOSE The recommended duration of adjuvant fluoropyrimidine and oxaliplatin chemotherapy for patients with stage III colon cancer is based on tumor classification into clinically low-risk (T1-3 N1) and high-risk (T4 or N2) groups. We determined whether Immunoscore can enhance prognostication within these risk groups. MATERIALS AND METHODS Patients with stage III colon carcinomas (N = 600) were randomly selected from the infusional fluorouracil, leucovorin, and oxaliplatin arm of adjuvant trial NCCTG N0147 (Alliance for Clinical Trials in Oncology). Tumors were evaluated for Immunoscore that quantifies CD3+ and CD8+ T-cell densities in the tumor center and invasive margin by digital image analysis. Disease-free survival (DFS) by Immunoscore was analyzed using a multivariable Cox regression model in each risk group with adjustment for covariates including KRAS, BRAF V600E, and mismatch repair status. RESULTS Of 559 cancers with Immunoscore data, 299 (53.5%) were classified as clinically low-risk (T1-3 N1) and 260 (46.5%) as clinically high-risk (T4 and/or N2). Among patients with low-risk tumors, those with Immunoscore-Low versus Immunoscore-High tumors had significantly worse 5-year DFS rates (77.5% v 91.8%; hazard ratio, 1.70; 95% CI, 1.03 to 2.79; P = .037). Among patients with high-risk tumors, those with Immunoscore-Low versus Immunoscore-High tumors also had significantly worse DFS (55.3% v 70.3%; hazard ratio, 1.65; 95% CI, 1.11 to 2.47; P = .013). Tumors that were low-risk/Immunoscore-Low had similar outcomes as did tumors that were high-risk/Immunoscore-High ( P = .174). Prognostication was significantly improved in multivariable models where Immunoscore was added to clinical risk parameters and limited biomarkers (likelihood ratio test P = .0003). CONCLUSION Immunoscore can refine patient prognosis beyond clinical risk group classification, suggesting its potential utility for adjuvant decision making.
[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
Kuo, Phillip H. , Hesterman, Jacob , Wei, Xiao X. , Michalski, Jeff M. , Ghebremariam, Samson, Brackman, Marcia, Wong, Connie, Benson, Taylor L., Rahbar, Kambiz , Kendi, A. Tuba , Fang, Bruno S. , Adra, Nabil , Armstrong, Andrew J. , Garje, Rohan , Wong, Connie, Benson, Taylor, Vogelzang, Nicholas J.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 5002-5002

10.1200/jco.2022.40.16_suppl.5002 Get It

5002 Background: In the phase 3 VISION study, gallium (68Ga) gozetotide (68Ga-PSMA-11) PET/CT imaging was used to determine eligibility for lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617). Given that 177Lu-PSMA-617 targets PSMA, we assessed the association between quantitative PSMA imaging parameters and treatment outcomes. Methods: In VISION, adults with mCRPC with ≥ 1 PSMA-positive (+) and no PSMA-negative lesions meeting the exclusion criteria were enrolled. In this sub-study, the association between imaging data from pre-enrollment 68Ga-PSMA-11 PET/CT scans of pts in the 177Lu-PSMA-617 group and clinical outcomes was assessed. Imaging data meeting quality requirements were analyzed for 548/551 pts. PSMA expression was quantified by 5 PET parameters: PSMA+ lesions by region, mean standardized uptake value (SUVmean), maximum SUV (SUVmax), PSMA+ tumor volume, and tumor load (PSMA+ tumor volume × SUVmean). Parameters were extracted from the whole body and 4 regions. Association between PET parameters and radiographic progression-free survival (rPFS; primary objective), overall survival (OS), objective response rate (ORR), and prostate–specific antigen 50 (PSA50) response was assessed. Results: Most pts (92.7%) had PSMA uptake in bone. In both the whole-body and regional analyses, statistically significant associations of PSMA PET parameters to clinical outcomes were observed (whole-body data shown in Table). Higher whole-body SUVmean was associated with improved clinical outcomes; pts in the highest quartile (SUVmean: rPFS, ≥ 10.2; OS, ≥ 9.9) had a median rPFS and OS of 14.1 and 21.4 months, vs 5.8 and 14.5 months for those in the lowest quartile (< 6.0; < 5.7), respectively. Absence of PSMA+ lesions in bone, liver, and lymph node, and lower PSMA+ tumor load, were indicators of good prognosis. Conclusions: Higher SUVmean is strongly associated with improved outcomes with 177Lu-PSMA-617; clinical efficacy for different SUV levels vs the SoC arm is being assessed. Data support use of 68Ga-PSMA-11 PET/CT scan to identify pts who will benefit from PSMA-targeted radioligand therapy.[Table: see text]
Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).
Philip, Philip Agop, Bahary, Nathan , Kasi, Anup , Lima, Caio Max Sao Pedro Rocha , Alistar, Angela , Oberstein, Paul E. , Golan, Talia , Sahai, Vaibhav , Metges, Jean Philippe, Lacy, Jill , Salem, Mohamed E. , Bajor, David L. , Benson, Al B. , Sahai, Vaibhav , Mahipal, Amit , Fountzilas, Christos , Lopez, Charles D. , Ducreux, Michel , Hammel, Pascal , Buyse, Marc , Cutsem, Eric Van

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 4023-4023

10.1200/jco.2022.40.16_suppl.4023 Get It

4023 Background: Metastatic pancreatic cancer (mPC) remains a deadly disease with very limited treatment options. FFX is a standard first-line therapy for mPC with a median overall survival (mOS) of 11.1 months. CPI-613 is a stable intermediate of a lipoate analog that inhibits pyruvate dehydrogenase and α-ketoglutarate dehydrogenase enzymes of the tricarboxylic cycle preferentially within the mitochondria of cancer cells. In a phase I study, CPI-613+mFFX was safe and exhibited promising signal of efficacy. Methods: A global, randomized phase 3 trial was conducted across 73 sites to investigate the efficacy and safety of CPI-613 in combination with mFFX compared to standard dose FFX in treatment-naïve patients with mPC. Treatment was administered in 2-weekly cycles until progression or intolerable toxicity. In the experimental arm, CPI-613 at 500 mg/m2 was given intravenously on days 1 and 3. The doses of irinotecan, oxaliplatin, and 5-fluorouracil in the experimental arm were 65 mg/m2, 140 mg/m2, and 2,400 mg/2, respectively. Primary endpoint was OS. Secondary endpoints were progression-free survival (PFS), overall response rate (ORR), duration of response, pharmacokinetics, patient reported outcomes and safety. Results: 528 patients were randomly assigned (266 in test and 262 in control arm). There were 362 deaths, with a mOS of 11.1 months for CPI-613+mFFX vs. 11.7 months for FFX [hazard ratio (HR), 0.95; 95% CI, 0.77 to 1.18; P = 0.655]; mPFS was 7.8 months vs. 8.0 months respectively [HR, 0.99; 95% CI, 0.76 to 1.29; P = 0.94]; ORR was 39% in the test arm vs. 34% in the control arm [ORR ratio, 1.23 (95% CI, 0.86 to 1.75)]. Grade ≥ 3 treatment-emergent adverse events with ≥ 10% frequency in CPI-613 plus mFFX vs. FFX arm were diarrhea (11.2% vs. 19.6%), hypokalemia (13.1% vs. 14.9%), anemia (13.9% vs. 13.6%), neutropenia (11.2% vs. 14.0%), thrombocytopenia (11.6% vs. 13.6%) and fatigue (10.8% vs. 11.5%). Conclusions: The addition of CPI-613 to mFFX failed to show significant improvements of ORR, PFS or OS. The mFFX in the test arm that had the lowest prospectively tested doses of FFX was without compromise on PFS or OS and may be considered as a reference for future FFX administration. Clinical trial information: NCT03504423.
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Oyer, Randall A. , Hurley, Patricia A. , Boehmer, Leigh , Bruinooge, Suanna S. , Levit, Kathryn , Barrett, Nadine J. , Benson, Al B. , Bernick, Lea Ann, Byatt, Leslie, Charlot, Marjory , Crews, Jennie R. , DeLeon, Kyle, Green, Sybil, Guerra, Carmen E. , Hamroun, Leila, Hardy, Claudia M. , Hempstead, Bridgette, Jeames, Sanford , Mann, Mel , Matin, Khalid , McCaskill‐Stevens, Worta , Merrill, Janette K. , Nowakowski, Grzegorz S. , Patel, Manali I. , Pressman, Alice , Segura, Juanita, Segarra-Vasquez, Barbara, Williams, Jen Hanley, Williams, J.E. Caerwyn , Winkfield, Karen M. , Yang, Eddy S. , Zwicker, Victoria, Pierce, Lori J. , Hurley, Patricia , Bruinooge, Suanna Steeby , Barrett, Nadine , Benson, Al , Fashoyin-Aje, Lola , Garrett-Mayer, Elizabeth , Gralow, Julie R , Guerra, Carmen E , Jeames, Sanford , Mann, Mel , Merrill, Janette , Nowakowski, Grzegorz S , Patel, Manali I , Pressman, Alice , Ramirez, Amelie G , Hanley Williams, Jen , Williams, James E , Winkfield, Karen M , Yang, Eddy S , Pierce, Lori J , Charlot, Marjory , Oyer, Randall A , Garrett‐Mayer, Elizabeth , Gralow, Julie R. , Segarra-Vasquez, Barbara

Mayo Clinic

Journal of Clinical Oncology | May 19, 2022 | Volume: 40 | Issue: 19 | Pages: 2163-2171

10.1200/jco.22.00754 | PMID 35588469 Get It

A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.
Infrapedicular approach to CT-guided thermal ablation in the thoracic spine
Burkett, Brian J. , Kim, Dong Kun , Benson, John C. , Burkett, Brian , Benson, John , Carr, Carrie, Carr, Carrie M. , Morris, Jonathan M.

Mayo Clinic

The Neuroradiology Journal | May 18, 2022 | Volume: 35 | Issue: 6 | Pages: 736-741

10.1177/19714009221096827 | PMID 35574645 Get It

Objectives The aim of this study is to introduce the infrapedicular approach to CT-guided spine interventions, a specialized technique that can safely expand the scope of spine lesions amenable to treatment, and to document the feasibility in a variety of procedural scenarios to the extent possible with a retrospective case series. Methods Data from 24 cases performed at a single institution over a 10-year period were retrospectively reviewed to assess the technical feasibility and safety profile of the technique. Results The infrapedicular approach enabled a technically satisfactory procedural result in 24 cases (mean age 63.9 years, range 35–83 years). Two peri-procedural complications occurred, including a small pneumothorax and a cerebrospinal fluid leak, both of which resolved with conservative treatment. No lasting injurious effects or additional complications were identified. The infrapedicular approach was found to be particularly useful in multiple technically challenging scenarios: it facilitates access to lesions in the inferior vertebral body, allows biopsy, cement augmentation, or ablation of high thoracic lesions difficult to treat due to limitations of steep angulation of fluoroscopy and CT scanners, and enables treatment of large lesions by using multiple overlapping probes.